AC-201 is a novel, highly selective and potent oral small-molecule inhibitor of TYK2/JAK1 that binds to the pseudo kinase ...
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was ...
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has initiated a U.S. Phase I study of ASC36 oral tablets ...
The IND clearance marks the transition of the first-in-class new drug from preclinical research into clinical development.
The first Phase 3 study of SKB378/WIN378 has been initiated evaluating two twice-yearly doses. A second Phase 3 trial is ...
HIMSS26 APAC a flagship digital health event for the Asia-Pacific region at Marina Bay Sands Expo and Convention Centre in ...
AstraZeneca’s ETCAMAH ® (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, ...
Rznomics Inc. (KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, ...
Which is the closing point, and the uncomfortable one. Each corner is currently legislating as though the unit of regulation ...
CelluPro, a biotechnology company specializing in serum-free cell culture media and bioprocess solutions, has achieved EXCiPACT™ GMP Certification for Pharmaceutical Auxiliary Materials (PAMs), ...
Partnership integrates Evinova’s Unified Trial Solution with Lothar Medical’s three-in-one respiratory device to streamline ...
Taiwanese biomaterials firm targets strategic distribution partnerships in Thailand across dental, surgical and regenerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results